Glatiramer acetate for relapsing multiple sclerosis.
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D000068717:Glatiramer Acetate; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000502:physiology
D000276:Adjuvants, Immunologic; D010455:Peptides; D000068717:Glatiramer Acetate